Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2018 Filed Feb 21, 2018 00:29 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,180 | $45.84 | $99,931.20 |
DisclosureSEC source: 0001140361-18-009190 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774 Underlying: Common Stock · 1,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 2,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,548 Underlying: Common Stock · 2,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vest in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vest in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. The RSUs vest in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560 Underlying: Common Stock · 560 shares Expires 2028-02-13 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 90,816 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,816 Underlying: Common Stock · 90,816 shares Expires 2028-02-13 F6 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,828 | $178.26 | $325,859.28 |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,218 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008869 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · derivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,000 | $175.34 | $701,356.80 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $175.0201 to a high of $176.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 4,000 | $38.80 | $155,180.00 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · derivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,883 | $179.27 | $337,559.76 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $179.06 to a high of $179.58 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,912 | $178.36 | $876,082.71 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,060,995 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $178.0101 to a high of $178.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 11,205 | $177.63 | $1,990,383.37 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,907 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $177.01 to a high of $178.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-006391 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · derivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 600 | $179.71 | $107,826.00 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: Represents the weighted average sales price of the shares sold ranging from a low of $179.33 to a high of $180.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,400 | $178.73 | $428,944.08 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,712 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: Represents the weighted average sales price of the shares sold ranging from a low of $178.13 to a high of $179.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,800 | $177.62 | $674,945.74 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: Represents the weighted average sales price of the shares sold ranging from a low of $177.24 to a high of $178.18 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,600 | $176.87 | $636,746.04 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,912 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: Represents the weighted average sales price of the shares sold ranging from a low of $176.255 to a high of $177.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,400 | $175.67 | $421,603.92 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,512 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: Represents the weighted average sales price of the shares sold ranging from a low of $175.23 to a high of $176.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,200 | $174.86 | $909,295.92 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,912 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $174.22 to a high of $175.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · derivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $183.03 | $18,303.00 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 8,668 | $182.39 | $1,580,986.86 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,212 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $182.02 to a high of $182.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,532 | $181.70 | $1,368,543.31 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,880 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $181.01 to a high of $182.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,700 | $180.46 | $306,778.94 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,412 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $180.0001 to a high of $180.7601 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · derivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 15,840 | $168.03 | $2,661,554.02 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: Represents the weighted average sales price of the shares sold ranging from a low of $167.6001 to a high of $168.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,160 | $167.03 | $360,781.13 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,952 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: Represents the weighted average sales price of the shares sold ranging from a low of $166.60 to a high of $167.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · derivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 304 | $165.53 | $50,321.67 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: Represents the weighted average sales price of the shares sold ranging from a low of $165.53 to a high of $165.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 15,496 | $164.97 | $2,556,403.01 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,416 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $164.51 to a high of $165.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,200 | $164.13 | $361,083.80 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,912 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $163.50 to a high of $164.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · derivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,700 | $165.48 | $612,261.57 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $165.355 to a high of $165.93 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 14,300 | $165.06 | $2,360,368.01 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,812 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $164.35 to a high of $165.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 23:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 12,500 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-18-001112 · doc1.xml · derivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 12,500 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 12,500 | $38.80 | $484,937.50 |
DisclosureSEC source: 0001140361-18-001112 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 39 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 29, 2017. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 02:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 18,000 | Not disclosed Strike: $38.80 | Not disclosed |
DisclosureSEC source: 0001140361-17-043146 · doc1.xml · derivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,500 Underlying: Common Stock · 18,000 shares Expires 2018-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · price: Not applicable. F10 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 02:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 11,700 | $154.01 | $1,801,962.63 |
DisclosureSEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046,573 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: Represents the weighted average sales price of the shares sold ranging from a low of $153.76 to a high of $154.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 02:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,100 | $153.32 | $628,615.69 |
DisclosureSEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,273 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: Represents the weighted average sales price of the shares sold ranging from a low of $152.73 to a high of $153.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 02:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,200 | $151.97 | $334,323.88 |
DisclosureSEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,373 F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: Represents the weighted average sales price of the shares sold ranging from a low of $151.53 to a high of $152.51per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 02:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,000 | $38.80 | $698,310.00 |
DisclosureSEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.